These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
þ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Delaware | 13-3668640 | |
(State or other jurisdiction of | (I.R.S. Employer | |
incorporation or organization) | Identification No.) |
Large accelerated filer
þ
|
Accelerated filer o | Non-accelerated filer o | Smaller reporting company o | |||
|
(Do not check if smaller reporting company) |
Page | ||||||||
PART I FINANCIAL INFORMATION
|
||||||||
Item 1. Financial Statements
|
||||||||
1 | ||||||||
2 | ||||||||
3 | ||||||||
4 | ||||||||
5 | ||||||||
19 | ||||||||
26 | ||||||||
26 | ||||||||
|
||||||||
26 | ||||||||
27 | ||||||||
27 | ||||||||
27 | ||||||||
29 | ||||||||
EX-31.1 | ||||||||
EX-31.2 | ||||||||
EX-32.1 | ||||||||
EX-32.2 | ||||||||
EX-101 INSTANCE DOCUMENT | ||||||||
EX-101 SCHEMA DOCUMENT | ||||||||
EX-101 CALCULATION LINKBASE DOCUMENT | ||||||||
EX-101 LABELS LINKBASE DOCUMENT | ||||||||
EX-101 PRESENTATION LINKBASE DOCUMENT | ||||||||
EX-101 DEFINITION LINKBASE DOCUMENT |
October 2, 2010 | December 31, 2009 | |||||||
ASSETS
|
||||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$ | 262,792 | $ | 341,111 | ||||
Short-term investments
|
574,306 | 289,146 | ||||||
Accounts receivable, less allowances for doubtful accounts and
sales returns of $7,230 and $6,723 at October 2, 2010 and
December 31, 2009, respectively
|
337,562 | 314,247 | ||||||
Inventories
|
208,339 | 178,666 | ||||||
Other current assets
|
55,328 | 49,206 | ||||||
|
||||||||
Total current assets
|
1,438,327 | 1,172,376 | ||||||
Property, plant and equipment, net
|
214,773 | 210,926 | ||||||
Intangible assets, net
|
183,182 | 182,165 | ||||||
Goodwill
|
292,424 | 293,077 | ||||||
Other assets
|
76,940 | 49,387 | ||||||
|
||||||||
Total assets
|
$ | 2,205,646 | $ | 1,907,931 | ||||
|
||||||||
|
||||||||
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
Current liabilities:
|
||||||||
Notes payable and debt
|
$ | 92,243 | $ | 131,772 | ||||
Accounts payable
|
63,332 | 49,573 | ||||||
Accrued employee compensation
|
38,475 | 37,050 | ||||||
Deferred revenue and customer advances
|
120,850 | 94,680 | ||||||
Accrued income taxes
|
29,896 | 13,267 | ||||||
Accrued warranty
|
10,767 | 10,109 | ||||||
Other current liabilities
|
61,847 | 58,117 | ||||||
|
||||||||
Total current liabilities
|
417,410 | 394,568 | ||||||
Long-term liabilities:
|
||||||||
Long-term debt
|
700,000 | 500,000 | ||||||
Long-term portion of retirement benefits
|
67,574 | 69,044 | ||||||
Long-term income tax liability
|
75,639 | 72,604 | ||||||
Other long-term liabilities
|
21,761 | 22,766 | ||||||
|
||||||||
Total long-term liabilities
|
864,974 | 664,414 | ||||||
|
||||||||
Total liabilities
|
1,282,384 | 1,058,982 | ||||||
|
||||||||
Commitments and contingencies (Notes 5, 6, 7 and 11)
|
||||||||
|
||||||||
Stockholders’ equity:
|
||||||||
Preferred stock, par value $0.01 per share, 5,000 shares
authorized, none issued at October 2, 2010 and
December 31, 2009
|
— | — | ||||||
Common stock, par value $0.01 per share, 400,000 shares
authorized, 149,750 and 148,831 shares issued, 91,210 and
94,118 shares outstanding at October 2, 2010 and
December 31, 2009, respectively
|
1,497 | 1,488 | ||||||
Additional paid-in capital
|
884,435 | 808,345 | ||||||
Retained earnings
|
2,491,875 | 2,236,716 | ||||||
Treasury stock, at cost, 58,540 and 54,713 shares at October 2, 2010
and December 31, 2009, respectively
|
(2,458,067 | ) | (2,213,174 | ) | ||||
Accumulated other comprehensive income
|
3,522 | 15,574 | ||||||
|
||||||||
Total stockholders’ equity
|
923,262 | 848,949 | ||||||
|
||||||||
Total liabilities and stockholders’ equity
|
$ | 2,205,646 | $ | 1,907,931 | ||||
|
1
Three Months Ended | ||||||||
October 2, 2010 | October 3, 2009 | |||||||
Product sales
|
$ | 282,934 | $ | 259,532 | ||||
Service sales
|
118,104 | 114,431 | ||||||
|
||||||||
Total net sales
|
401,038 | 373,963 | ||||||
|
||||||||
Cost of product sales
|
113,345 | 104,038 | ||||||
Cost of service sales
|
49,640 | 49,105 | ||||||
|
||||||||
Total cost of sales
|
162,985 | 153,143 | ||||||
|
||||||||
|
||||||||
Gross profit
|
238,053 | 220,820 | ||||||
|
||||||||
Selling and administrative expenses
|
111,306 | 102,675 | ||||||
|
||||||||
Research and development expenses
|
20,524 | 19,310 | ||||||
|
||||||||
Purchased intangibles amortization
|
2,408 | 2,723 | ||||||
|
||||||||
|
||||||||
Operating income
|
103,815 | 96,112 | ||||||
|
||||||||
Interest expense
|
(3,810 | ) | (2,864 | ) | ||||
|
||||||||
Interest income
|
516 | 785 | ||||||
|
||||||||
|
||||||||
Income from operations before income taxes
|
100,521 | 94,033 | ||||||
|
||||||||
Provision for income taxes
|
5,802 | 18,097 | ||||||
|
||||||||
|
||||||||
Net income
|
$ | 94,719 | $ | 75,936 | ||||
|
||||||||
|
||||||||
Net income per basic common share
|
$ | 1.03 | $ | 0.80 | ||||
|
||||||||
Weighted-average number of basic common shares
|
91,714 | 95,235 | ||||||
|
||||||||
Net income per diluted common share
|
$ | 1.02 | $ | 0.79 | ||||
|
||||||||
Weighted-average number of diluted common shares and
equivalents
|
93,286 | 96,513 |
2
Nine Months Ended | ||||||||
October 2, 2010 | October 3, 2009 | |||||||
Product sales
|
$ | 811,401 | $ | 740,501 | ||||
Service sales
|
348,392 | 329,351 | ||||||
|
||||||||
Total net sales
|
1,159,793 | 1,069,852 | ||||||
|
||||||||
Cost of product sales
|
317,640 | 285,946 | ||||||
Cost of service sales
|
146,410 | 138,805 | ||||||
|
||||||||
Total cost of sales
|
464,050 | 424,751 | ||||||
|
||||||||
|
||||||||
Gross profit
|
695,743 | 645,101 | ||||||
|
||||||||
Selling and administrative expenses
|
324,938 | 311,417 | ||||||
|
||||||||
Research and development expenses
|
61,407 | 57,364 | ||||||
|
||||||||
Purchased intangibles amortization
|
7,642 | 8,022 | ||||||
|
||||||||
|
||||||||
Operating income
|
301,756 | 268,298 | ||||||
|
||||||||
Interest expense
|
(10,045 | ) | (8,643 | ) | ||||
|
||||||||
Interest income
|
1,293 | 2,288 | ||||||
|
||||||||
|
||||||||
Income from operations before income taxes
|
293,004 | 261,943 | ||||||
|
||||||||
Provision for income taxes
|
37,845 | 42,753 | ||||||
|
||||||||
|
||||||||
Net income
|
$ | 255,159 | $ | 219,190 | ||||
|
||||||||
|
||||||||
Net income per basic common share
|
$ | 2.75 | $ | 2.28 | ||||
|
||||||||
Weighted-average number of basic common shares
|
92,647 | 96,215 | ||||||
|
||||||||
Net income per diluted common share
|
$ | 2.71 | $ | 2.26 | ||||
|
||||||||
Weighted-average number of diluted common shares and
equivalents
|
94,271 | 97,027 |
3
Nine Months Ended | ||||||||
October 2, 2010 | October 3, 2009 | |||||||
Cash flows from operating activities:
|
||||||||
Net income
|
$ | 255,159 | $ | 219,190 | ||||
Adjustments to reconcile net income to net cash provided by
operating activities:
|
||||||||
Provisions for doubtful accounts on accounts receivable
|
1,414 | 844 | ||||||
Provisions on inventory
|
7,309 | 5,577 | ||||||
Stock-based compensation
|
18,558 | 21,757 | ||||||
Deferred income taxes
|
(4,669 | ) | 1,696 | |||||
Depreciation
|
25,897 | 23,782 | ||||||
Amortization of intangibles
|
19,621 | 18,790 | ||||||
Change in operating assets and liabilities, net of acquisitions:
|
||||||||
(Increase) decrease in accounts receivable
|
(20,713 | ) | 12,070 | |||||
Increase in inventories
|
(35,771 | ) | (18,619 | ) | ||||
(Increase) decrease in other current assets
|
(1,325 | ) | 3,652 | |||||
Increase in other assets
|
(1,256 | ) | (1,584 | ) | ||||
Increase in accounts payable and other current
liabilities
|
36,311 | 906 | ||||||
Increase in deferred revenue and customer advances
|
23,335 | 14,245 | ||||||
Decrease in other liabilities
|
(101 | ) | (3,902 | ) | ||||
|
||||||||
Net cash provided by operating activities
|
323,769 | 298,404 | ||||||
Cash flows from investing activities:
|
||||||||
Additions to property, plant, equipment and software
capitalization
|
(47,277 | ) | (80,399 | ) | ||||
Business acquisitions, net of cash acquired
|
— | (36,086 | ) | |||||
Purchase of short-term investments
|
(924,727 | ) | (317,342 | ) | ||||
Maturity of short-term investments
|
639,567 | 129,611 | ||||||
|
||||||||
Net cash used in investing activities
|
(332,437 | ) | (304,216 | ) | ||||
Cash flows from financing activities:
|
||||||||
Proceeds from debt issuances
|
315,116 | 169,024 | ||||||
Payments on debt
|
(154,645 | ) | (64,393 | ) | ||||
Payments of debt issuance costs
|
(1,498 | ) | — | |||||
Proceeds from stock plans
|
26,850 | 8,159 | ||||||
Purchase of treasury shares
|
(244,893 | ) | (157,212 | ) | ||||
Excess tax benefit related to stock option plans
|
5,149 | — | ||||||
(Payments for) proceeds from debt swaps and other derivative
contracts
|
(4,968 | ) | 4,495 | |||||
|
||||||||
Net cash used in financing activities
|
(58,889 | ) | (39,927 | ) | ||||
Effect of exchange rate changes on cash and cash equivalents
|
(10,762 | ) | 7,634 | |||||
|
||||||||
Decrease in cash and cash equivalents
|
(78,319 | ) | (38,105 | ) | ||||
Cash and cash equivalents at beginning of period
|
341,111 | 428,522 | ||||||
|
||||||||
Cash and cash equivalents at end of period
|
$ | 262,792 | $ | 390,417 | ||||
|
4
5
Quoted Prices | ||||||||||||||||
in Active | Significant | |||||||||||||||
Markets | Other | Significant | ||||||||||||||
for Identical | Observable | Unobservable | ||||||||||||||
Total at | Assets | Inputs | Inputs | |||||||||||||
October 2, 2010 | (Level 1) | (Level 2) | (Level 3) | |||||||||||||
Assets:
|
||||||||||||||||
Cash equivalents
|
$ | 106,273 | $ | — | $ | 106,273 | $ | — | ||||||||
Short-term investments
|
574,306 | — | 574,306 | — | ||||||||||||
Waters Retirement Restoration Plan assets
|
18,771 | — | 18,771 | — | ||||||||||||
Foreign currency exchange contract
agreements
|
375 | — | 375 | — | ||||||||||||
|
||||||||||||||||
Total
|
$ | 699,725 | $ | — | $ | 699,725 | $ | — | ||||||||
|
||||||||||||||||
|
||||||||||||||||
Liabilities:
|
||||||||||||||||
Foreign currency exchange contract
agreements
|
$ | 664 | $ | — | $ | 664 | $ | — | ||||||||
|
||||||||||||||||
Total
|
$ | 664 | $ | — | $ | 664 | $ | — | ||||||||
|
Quoted Prices | ||||||||||||||||
in Active | Significant | |||||||||||||||
Markets | Other | Significant | ||||||||||||||
Total at | for Identical | Observable | Unobservable | |||||||||||||
December 31, | Assets | Inputs | Inputs | |||||||||||||
2009 | (Level 1) | (Level 2) | (Level 3) | |||||||||||||
Assets:
|
||||||||||||||||
Cash equivalents
|
$ | 181,925 | $ | — | $ | 181,925 | $ | — | ||||||||
Short-term investments
|
289,146 | — | 289,146 | — | ||||||||||||
Waters Retirement Restoration Plan assets
|
17,955 | — | 17,955 | — | ||||||||||||
Foreign currency exchange contract
agreements
|
237 | — | 237 | — | ||||||||||||
|
||||||||||||||||
Total
|
$ | 489,263 | $ | — | $ | 489,263 | $ | — | ||||||||
|
||||||||||||||||
|
||||||||||||||||
Liabilities:
|
||||||||||||||||
Foreign currency exchange contract
agreements
|
$ | 400 | $ | — | $ | 400 | $ | — | ||||||||
|
||||||||||||||||
Total
|
$ | 400 | $ | — | $ | 400 | $ | — | ||||||||
|
6
7
Balance at | Balance at | |||||||||||||||
Beginning | Accruals for | Settlements | End of | |||||||||||||
of Period | Warranties | Made | Period | |||||||||||||
Accrued warranty liability:
|
||||||||||||||||
October 2, 2010
|
$ | 10,109 | $ | 4,849 | $ | (4,191 | ) | $ | 10,767 | |||||||
October 3, 2009
|
$ | 10,276 | $ | 4,485 | $ | (4,414 | ) | $ | 10,347 |
October 2, 2010 | December 31, 2009 | |||||||
Raw materials
|
$ | 67,670 | $ | 57,223 | ||||
Work in progress
|
19,709 | 15,419 | ||||||
Finished goods
|
120,960 | 106,024 | ||||||
|
||||||||
Total inventories
|
$ | 208,339 | $ | 178,666 | ||||
|
8
October 2, 2010 | December 31, 2009 | |||||||||||||||||||||||
Weighted- | Weighted- | |||||||||||||||||||||||
Gross | Average | Gross | Average | |||||||||||||||||||||
Carrying | Accumulated | Amortization | Carrying | Accumulated | Amortization | |||||||||||||||||||
Amount | Amortization | Period | Amount | Amortization | Period | |||||||||||||||||||
Purchased intangibles
|
$ | 135,568 | $ | 68,776 | 10 years | $ | 136,604 | $ | 61,751 | 10 years | ||||||||||||||
Capitalized software
|
228,695 | 126,957 | 5 years | 217,102 | 122,920 | 5 years | ||||||||||||||||||
Licenses
|
9,795 | 8,856 | 7 years | 9,637 | 8,328 | 8 years | ||||||||||||||||||
Patents and other
intangibles
|
28,203 | 14,490 | 8 years | 24,185 | 12,364 | 8 years | ||||||||||||||||||
|
||||||||||||||||||||||||
|
||||||||||||||||||||||||
Total
|
$ | 402,261 | $ | 219,079 | 7 years | $ | 387,528 | $ | 205,363 | 7 years | ||||||||||||||
|
9
October 2, 2010 | December 31, 2009 | |||||||
Lines of credit
|
$ | 12,243 | $ | 11,772 | ||||
2007 Credit Agreement, due January 2012
|
80,000 | 120,000 | ||||||
|
||||||||
Total notes payable and debt
|
92,243 | 131,772 | ||||||
|
||||||||
|
||||||||
Senior unsecured notes — Series A - 3.75%, due February 2015
|
100,000 | — | ||||||
Senior unsecured notes — Series B - 5.00%, due February 2020
|
100,000 | — | ||||||
2007 Credit Agreement, due January 2012
|
500,000 | 500,000 | ||||||
|
||||||||
Total long-term debt
|
700,000 | 500,000 | ||||||
|
||||||||
|
||||||||
Total debt
|
$ | 792,243 | $ | 631,772 | ||||
|
10
October 2, 2010 | October 3, 2009 | |||||||
Balance at the beginning of the period
|
$ | 77,924 | $ | 77,295 | ||||
Realization of uncertain U.K. tax benefits
|
(9,996 | ) | — | |||||
Realization of uncertain pre-acquisition tax benefits
|
(1,500 | ) | — | |||||
Realization of uncertain legal entity reorganization
tax benefits
|
— | (4,555 | ) | |||||
Increase in other uncertain tax benefits
|
3,469 | 3,395 | ||||||
|
||||||||
Balance at the end of the period
|
$ | 69,897 | $ | 76,135 | ||||
|
11
12
Three Months Ended | Nine Months Ended | |||||||||||||||
October 2, | October 3, | October 2, | October 3, | |||||||||||||
2010 | 2009 | 2010 | 2009 | |||||||||||||
Cost of sales
|
$ | 623 | $ | 687 | $ | 1,852 | $ | 2,122 | ||||||||
Selling and administrative expenses
|
4,829 | 5,467 | 14,364 | 16,992 | ||||||||||||
Research and development expenses
|
792 | 1,097 | 2,342 | 2,643 | ||||||||||||
|
||||||||||||||||
Total stock-based compensation
|
$ | 6,244 | $ | 7,251 | $ | 18,558 | $ | 21,757 | ||||||||
|
Options Issued and Significant Assumptions Used to Estimate | ||||||||
Option Fair Values | October 2, 2010 | October 3, 2009 | ||||||
Options issued in thousands
|
32 | 28 | ||||||
Risk-free interest rate
|
3.0 | % | 2.0 | % | ||||
Expected life in years
|
6 | 6 | ||||||
Expected volatility
|
0.293 | 0.570 | ||||||
Expected dividends
|
— | — |
Weighted-Average Exercise Price and Fair Value of Options on | ||||||||
the Date of Grant | October 2, 2010 | October 3, 2009 | ||||||
Exercise price
|
$ | 61.63 | $ | 38.09 | ||||
Fair value
|
$ | 21.40 | $ | 20.71 |
13
Weighted-Average | ||||||||||||
Number of Shares | Price per Share | Exercise Price | ||||||||||
Outstanding at December 31, 2009
|
6,857 | $21.05 to $80.97 | $ | 47.58 | ||||||||
Granted
|
32 | $ | 61.63 | $ | 61.63 | |||||||
Exercised
|
(648 | ) | $21.39 to $72.06 | $ | 37.61 | |||||||
Canceled
|
(26 | ) | $49.31 to $72.06 | $ | 71.93 | |||||||
|
||||||||||||
Outstanding at October 2, 2010
|
6,215 | $21.05 to $80.97 | $ | 48.59 | ||||||||
|
Weighted-Average | ||||||||
Shares | Price | |||||||
Unvested at December 31, 2009
|
783 | $ | 45.30 | |||||
Granted
|
217 | $ | 62.24 | |||||
Vested
|
(216 | ) | $ | 46.97 | ||||
Forfeited
|
(25 | ) | $ | 47.67 | ||||
|
||||||||
Unvested at October 2, 2010
|
759 | $ | 49.59 | |||||
|
Three Months Ended October 2, 2010 | ||||||||||||
Weighted- | ||||||||||||
Net Income | Average Shares | Per Share | ||||||||||
(Numerator) | (Denominator) | Amount | ||||||||||
Net income per basic common share
|
$ | 94,719 | 91,714 | $ | 1.03 | |||||||
|
||||||||||||
Effect of dilutive stock option, restricted
stock and restricted stock unit securities:
|
||||||||||||
Outstanding
|
1,535 | |||||||||||
Exercised and cancellations
|
37 | |||||||||||
|
||||||||||||
Net income per diluted common share
|
$ | 94,719 | 93,286 | $ | 1.02 | |||||||
|
14
Three Months Ended October 3, 2009 | ||||||||||||
Weighted- | ||||||||||||
Net Income | Average Shares | Per Share | ||||||||||
(Numerator) | (Denominator) | Amount | ||||||||||
Net income per basic common share
|
$ | 75,936 | 95,235 | $ | 0.80 | |||||||
|
||||||||||||
Effect of dilutive stock option, restricted
stock and restricted stock unit securities:
|
||||||||||||
Outstanding
|
1,260 | |||||||||||
Exercised and cancellations
|
18 | |||||||||||
|
||||||||||||
Net income per diluted common share
|
$ | 75,936 | 96,513 | $ | 0.79 | |||||||
|
Nine Months Ended October 2, 2010 | ||||||||||||
Weighted- | ||||||||||||
Net Income | Average Shares | Per Share | ||||||||||
(Numerator) | (Denominator) | Amount | ||||||||||
Net income per basic common share
|
$ | 255,159 | 92,647 | $ | 2.75 | |||||||
|
||||||||||||
Effect of dilutive stock option, restricted
stock and restricted stock unit securities:
|
||||||||||||
Outstanding
|
1,470 | |||||||||||
Exercised and cancellations
|
154 | |||||||||||
|
||||||||||||
Net income per diluted common share
|
$ | 255,159 | 94,271 | $ | 2.71 | |||||||
|
Nine Months Ended October 3, 2009 | ||||||||||||
Weighted- | ||||||||||||
Net Income | Average Shares | Per Share | ||||||||||
(Numerator) | (Denominator) | Amount | ||||||||||
Net income per basic common share
|
$ | 219,190 | 96,215 | $ | 2.28 | |||||||
|
||||||||||||
Effect of dilutive stock option, restricted
stock and restricted stock unit securities:
|
||||||||||||
Outstanding
|
752 | |||||||||||
Exercised and cancellations
|
60 | |||||||||||
|
||||||||||||
Net income per diluted common share
|
$ | 219,190 | 97,027 | $ | 2.26 | |||||||
|
15
Three Months Ended | Nine Months Ended | |||||||||||||||
October 2, | October 3, | October 2, | October 3, | |||||||||||||
2010 | 2009 | 2010 | 2009 | |||||||||||||
Net income
|
$ | 94,719 | $ | 75,936 | $ | 255,159 | $ | 219,190 | ||||||||
Foreign currency translation
|
39,474 | 9,916 | (12,356 | ) | 25,872 | |||||||||||
Net appreciation and realized gains on
derivative instruments
|
— | 798 | — | 2,675 | ||||||||||||
Income tax expense
|
— | (279 | ) | — | (936 | ) | ||||||||||
|
||||||||||||||||
Net appreciation and realized gains on
derivative instruments, net of tax
|
— | 519 | — | 1,739 | ||||||||||||
|
||||||||||||||||
Net foreign currency adjustments
|
39,474 | 10,435 | (12,356 | ) | 27,611 | |||||||||||
Unrealized gains (losses) on investments
before income taxes
|
24 | 12 | 24 | (20 | ) | |||||||||||
Income tax (expense) benefit
|
(8 | ) | (4 | ) | (8 | ) | 7 | |||||||||
|
||||||||||||||||
Unrealized gains (losses) on investments, net of tax
|
16 | 8 | 16 | (13 | ) | |||||||||||
Retirement liability adjustment, net of tax
|
175 | (35 | ) | 288 | 306 | |||||||||||
|
||||||||||||||||
Other comprehensive income (loss)
|
39,665 | 10,408 | (12,052 | ) | 27,904 | |||||||||||
|
||||||||||||||||
Comprehensive income
|
$ | 134,384 | $ | 86,344 | $ | 243,107 | $ | 247,094 | ||||||||
|
Three Months Ended | ||||||||||||||||||||||||
October 2, 2010 | October 3, 2009 | |||||||||||||||||||||||
U.S. | U.S. Retiree | Non-U.S. | U.S. | U.S. Retiree | Non-U.S. | |||||||||||||||||||
Pension | Healthcare | Pension | Pension | Healthcare | Pension | |||||||||||||||||||
Plans | Plan | Plans | Plans | Plan | Plans | |||||||||||||||||||
Service cost
|
$ | 12 | $ | 118 | $ | 424 | $ | 23 | $ | 58 | $ | 424 | ||||||||||||
Interest cost
|
1,573 | 75 | 256 | 1,544 | 96 | 210 | ||||||||||||||||||
Expected return on plan
assets
|
(1,777 | ) | (60 | ) | (79 | ) | (1,678 | ) | (37 | ) | (83 | ) | ||||||||||||
Net amortization:
|
||||||||||||||||||||||||
Prior service (credit)
cost
|
— | (14 | ) | — | 37 | (14 | ) | — | ||||||||||||||||
Net actuarial loss (gain)
|
286 | — | (13 | ) | 98 | 3 | 12 | |||||||||||||||||
|
||||||||||||||||||||||||
Net periodic pension cost
|
$ | 94 | $ | 119 | $ | 588 | $ | 24 | $ | 106 | $ | 563 | ||||||||||||
|
16
Nine Months Ended | ||||||||||||||||||||||||
October 2, 2010 | October 3, 2009 | |||||||||||||||||||||||
U.S. | U.S. Retiree | Non-U.S. | U.S. | U.S. Retiree | Non-U.S. | |||||||||||||||||||
Pension | Healthcare | Pension | Pension | Healthcare | Pension | |||||||||||||||||||
Plans | Plan | Plans | Plans | Plan | Plans | |||||||||||||||||||
Service cost
|
$ | 42 | $ | 310 | $ | 1,272 | $ | 69 | $ | 174 | $ | 1,272 | ||||||||||||
Interest cost
|
4,743 | 281 | 768 | 4,632 | 288 | 630 | ||||||||||||||||||
Expected return on plan
assets
|
(5,347 | ) | (166 | ) | (237 | ) | (5,034 | ) | (111 | ) | (249 | ) | ||||||||||||
Net amortization:
|
||||||||||||||||||||||||
Prior service (credit)
cost
|
— | (40 | ) | — | 111 | (42 | ) | — | ||||||||||||||||
Net actuarial loss (gain)
|
810 | — | (39 | ) | 294 | 9 | 36 | |||||||||||||||||
|
||||||||||||||||||||||||
Net periodic pension cost
|
$ | 248 | $ | 385 | $ | 1,764 | $ | 72 | $ | 318 | $ | 1,689 | ||||||||||||
|
Three Months Ended | Nine Months Ended | |||||||||||||||
October 2, 2010 | October 3, 2009 | October 2, 2010 | October 3, 2009 | |||||||||||||
Product net sales:
|
||||||||||||||||
Waters instrument systems
|
$ | 185,526 | $ | 172,623 | $ | 526,627 | $ | 486,393 | ||||||||
Chemistry
|
65,595 | 61,919 | 195,144 | 180,291 | ||||||||||||
TA instrument systems
|
31,813 | 24,990 | 89,630 | 73,817 | ||||||||||||
|
||||||||||||||||
Total product sales
|
282,934 | 259,532 | 811,401 | 740,501 | ||||||||||||
|
||||||||||||||||
|
||||||||||||||||
Service net sales:
|
||||||||||||||||
Waters service
|
107,904 | 104,581 | 317,798 | 302,090 | ||||||||||||
TA service
|
10,200 | 9,850 | 30,594 | 27,261 | ||||||||||||
|
||||||||||||||||
Total service sales
|
118,104 | 114,431 | 348,392 | 329,351 | ||||||||||||
|
||||||||||||||||
|
||||||||||||||||
Total net sales
|
$ | 401,038 | $ | 373,963 | $ | 1,159,793 | $ | 1,069,852 | ||||||||
|
17
18
19
• | The benefits from higher sales volumes increased net income per diluted share in the 2010 Quarter and 2010 Period as compared to the 2009 Quarter and 2009 Period. | ||
• | The $8 million and $10 million of tax benefits recorded in the 2010 Quarter and 2010 Period, respectively, added $0.08 and $0.10 per diluted share to the 2010 Quarter and 2010 Period, respectively. | ||
• | The $6 million TA building lease termination expense recorded in the 2009 Period increased selling and administrative expenses and lowered net income per diluted share by $0.04 in the 2009 Period. | ||
• | The $5 million tax benefit recorded in the 2009 Period added $0.05 per diluted share to the 2009 Period. | ||
• | Lower weighted-average shares and equivalents, as a result of the Company’s share buyback program, increased net income per diluted share in the 2010 Quarter and 2010 Period as compared to the 2009 Quarter and 2009 Period. |
20
21
22
Nine Months Ended | ||||||||
October 2, 2010 | October 3, 2009 | |||||||
Net income
|
$ | 255,159 | $ | 219,190 | ||||
Depreciation and amortization
|
45,518 | 42,572 | ||||||
Stock-based compensation
|
18,558 | 21,757 | ||||||
Deferred income taxes
|
(4,669 | ) | 1,696 | |||||
Change in accounts receivable
|
(20,713 | ) | 12,070 | |||||
Change in inventories
|
(35,771 | ) | (18,619 | ) | ||||
Change in accounts payable and other current liabilities
|
36,311 | 906 | ||||||
Change in deferred revenue and customer advances
|
23,335 | 14,245 | ||||||
Other changes
|
6,041 | 4,587 | ||||||
|
||||||||
Net cash provided by operating activities
|
323,769 | 298,404 | ||||||
Net cash used in investing activities
|
(332,437 | ) | (304,216 | ) | ||||
Net cash used in financing activities
|
(58,889 | ) | (39,927 | ) | ||||
Effect of exchange rate changes on cash and cash equivalents
|
(10,762 | ) | 7,634 | |||||
|
||||||||
Decrease in cash and cash equivalents
|
$ | (78,319 | ) | $ | (38,105 | ) | ||
|
• | The change in accounts receivable in the 2010 Period compared to the 2009 Period was primarily attributable to timing of shipments and payments made by customers and higher sales volumes in the 2010 Period as compared to the 2009 Period. Days-sales-outstanding (“DSO”) increased to 77 days at October 2, 2010 from 71 days at October 3, 2009. | ||
• | The 2010 Period change in accounts payable and other current liabilities is a result of timing of payments to vendors and an increase in income taxes payable. Also, the 2009 Period includes a $6 million litigation payment and a $6 million TA building lease termination payment. | ||
• | Net cash provided from deferred revenue and customer advances in both the 2010 Period and the 2009 Period was a result of the installed base of customers renewing annual service contracts. | ||
• | Other changes were attributable to variation in the timing of various provisions, expenditures and accruals in other current assets, other assets and other liabilities. |
23
24
• | Current economic conditions and uncertainties; ability to access capital in volatile market conditions; changes in demand by the Company’s customers and various market sectors, particularly if they should reduce capital expenditures; the effect of mergers and acquisitions on customer demand; and ability to sustain and enhance service and consumable demand from the Company’s installed base of instruments. | |
• | Negative industry trends; introduction of competing products by other companies and loss of market share; pressures on prices from competitors and/or customers; regulatory, economic, and competitive obstacles to new product introductions; lack of acceptance of new products; and ability to obtain alternative sources for components and modules. | |
• | Foreign exchange rate fluctuations that could adversely affect translation of the Company’s future financial operating results and condition. | |
• | Increased regulatory burdens as the Company’s business evolves, especially with respect to the U.S. Securities and Exchange Commission, U.S. Food and Drug Administration, and U.S. Environmental Protection Agency, among others and regulatory, environmental and logistical obstacles affecting the distribution of the Company’s products and completion of purchase order documentation. |
25
• | Risks associated with lawsuits, including the Dearborn action and other legal actions, particularly involving claims for infringement of patents and other intellectual property rights. | |
• | The impact and costs incurred from changes in accounting principles and practices or tax rates; shifts in taxable income in jurisdictions with different effective tax rates; and the outcome of and costs associated with ongoing and future tax examinations or changes in respective country legislation affecting the Company’s effective rates. |
26
Maximum Dollar | ||||||||||||||||
Total Number of | Value of Shares | |||||||||||||||
Total | Shares Purchased | that May Yet Be | ||||||||||||||
Number of | Average | as Part of Publicly | Purchased Under | |||||||||||||
Shares | Price Paid | Announced Plans | the Plans or | |||||||||||||
Period | Purchased | per Share | or Programs (1) | Programs | ||||||||||||
July 4 to July 31, 2010
|
— | $ | — | — | $ | 167,521 | ||||||||||
August 1 to August 28, 2010
|
585 | $ | 63.49 | 585 | $ | 130,379 | ||||||||||
August 29 to October 2, 2010
|
425 | $ | 65.66 | 425 | $ | 102,474 | ||||||||||
|
||||||||||||||||
Total
|
1,010 | $ | 64.40 | 1,010 | $ | 102,474 | ||||||||||
|
(1) | The Company purchased 1.0 million shares of its outstanding common stock in the 2010 Quarter in open market transactions pursuant to a repurchase program that was announced in February 2009 (the “2009 Program”). The 2009 Program authorized the repurchase of up to $500 million of common stock in open market transactions over a two-year period. |
Exhibit | ||
Number | Description of Document | |
|
||
31.1
|
Chief Executive Officer Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
|
||
31.2
|
Chief Financial Officer Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
|
||
32.1 **
|
Chief Executive Officer Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
|
||
32.2 **
|
Chief Financial Officer Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
27
Exhibit | ||
Number | Description of Document | |
101 **
|
The following materials from Waters Corporation’s Quarterly Report on Form 10-Q for the quarter ended October 2, 2010, formatted in XBRL (Extensible Business Reporting Language): (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Operations, (iii) the Consolidated Statements of Cash Flows, and (iv) Condensed Notes to Consolidated Financial Statements. |
** | This exhibit shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any filing, except to the extent the Company specifically incorporates it by reference. |
28
Waters Corporation
|
||||
/s/ John Ornell | ||||
John Ornell | ||||
Vice President, Finance and
Administration and Chief Financial Officer |
||||
29
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
---|
DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
---|
No information found
Customers
Customer name | Ticker |
---|---|
Abbott Laboratories | ABT |
Laboratory Corporation of America Holdings | LH |
Pfizer Inc. | PFE |
No Suppliers Found
Price
Yield
Owner | Position | Direct Shares | Indirect Shares |
---|